US12648L6011 - Common Stock
NASDAQ:CTIC (12/7/2022, 2:11:02 PM)+0.11 (+1.91%)
|GICS Sector||Health Care|
|Earnings (Last)||11-07 2022-11-07/amc||Earnings (Next)||03-29 2023-03-29|
|Ins Owners||0.63%||Inst Owners||77.21%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. The company is headquartered in Seattle, Washington and currently employs 121 full-time employees. The firm is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). The company is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). The company also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. The company is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
CTI BIOPHARMA CORP
3101 Western Ave Ste 800
Seattle WASHINGTON 98121
CEO: Adam R. Craig
/PRNewswire/ -- The global ovarian cancer market is projected to continue to grow through the coming several years. The formation of mutational cells or...
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and...
/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in...
/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022....
Here you can normally see the latest stock twits on CTIC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.